Andrew Buchanan, Ph.D.

Principal Scientist, Biologics Engineering at AstraZeneca

Speaker

Andrew Buchanan is an experienced discovery scientist, contributing to 18 antibody-based drugs entering first-time in human clinical studies of which to date three are marketed products. He is a versatile critical thinker with 22 years of experience (Cambridge Antibody Technology, MedImmune and AstraZeneca), and has lead teams responsible for platform technologies and drug pipeline delivery to first in human studies. His current focus is on AI/ML for biologics, tissue targeting technologies and biologics science innovation. He was elected Fellow of the Royal Society of Chemistry in 2020 and with colleagues, postdocs, and PhD students, contributed to over 35 original manuscripts and patents.